133 related articles for article (PubMed ID: 35917493)
1. SATB2 Expression in Human Tumors: A Tissue Microarray Study on More Than 15 000 Tumors.
Dum D; Kromm D; Lennartz M; De Wispelaere N; Büscheck F; Luebke AM; Burandt E; Menz A; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Weidemann S; Fraune C; Möller K; Lebok P; Sauter G; Simon R; Uhlig R; Wilczak W; Minner S; Krech R; Bernreuther C; Marx A; Steurer S; Jacobsen F; Clauditz T; Krech T
Arch Pathol Lab Med; 2023 Apr; 147(4):451-464. PubMed ID: 35917493
[TBL] [Abstract][Full Text] [Related]
2. Loss of SATB2 Expression in Colorectal Carcinoma Is Associated With DNA Mismatch Repair Protein Deficiency and BRAF Mutation.
Ma C; Olevian DC; Lowenthal BM; Jayachandran P; Kozak MM; Chang DT; Pai RK
Am J Surg Pathol; 2018 Oct; 42(10):1409-1417. PubMed ID: 30001238
[TBL] [Abstract][Full Text] [Related]
3. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
4. Colitis-associated colorectal adenocarcinomas are frequently associated with non-intestinal mucin profiles and loss of SATB2 expression.
Iwaya M; Ota H; Tateishi Y; Nakajima T; Riddell R; Conner JR
Mod Pathol; 2019 Jun; 32(6):884-892. PubMed ID: 30710095
[TBL] [Abstract][Full Text] [Related]
5. SATB2 and CDX2 are prognostic biomarkers in DNA mismatch repair protein deficient colon cancer.
Ma C; Olevian D; Miller C; Herbst C; Jayachandran P; Kozak MM; Chang DT; Pai RK
Mod Pathol; 2019 Jul; 32(8):1217-1231. PubMed ID: 30962505
[TBL] [Abstract][Full Text] [Related]
6. SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.
Bellizzi AM
Histopathology; 2020 Jan; 76(2):251-264. PubMed ID: 31233624
[TBL] [Abstract][Full Text] [Related]
7. SATB2 as an Immunohistochemical Marker for Colorectal Adenocarcinoma: A Concise Review of Benefits and Pitfalls.
Berg KB; Schaeffer DF
Arch Pathol Lab Med; 2017 Oct; 141(10):1428-1433. PubMed ID: 28968158
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Utility of SATB2 in Metastatic Krukenberg Tumors of the Ovary: An Immunohistochemical Study of 70 Cases With Comparison to CDX2, CK7, CK20, Chromogranin, and Synaptophysin.
Yang C; Sun L; Zhang L; Zhou L; Zhao M; Peng Y; Niu D; Li Z; Huang X; Kang Q; Jia L; Lai J; Cao D
Am J Surg Pathol; 2018 Feb; 42(2):160-171. PubMed ID: 28914716
[TBL] [Abstract][Full Text] [Related]
9. Role of SATB2 in distinguishing the site of origin in glandular lesions of the bladder/urinary tract.
Giannico GA; Gown AM; Epstein JI; Revetta F; Bishop JA
Hum Pathol; 2017 Sep; 67():152-159. PubMed ID: 28711650
[TBL] [Abstract][Full Text] [Related]
10. SATB2 is a sensitive marker for lower gastrointestinal well-differentiated neuroendocrine tumors.
Li Z; Yuan J; Wei L; Zhou L; Mei K; Yue J; Gao H; Zhang M; Jia L; Kang Q; Huang X; Cao D
Int J Clin Exp Pathol; 2015; 8(6):7072-82. PubMed ID: 26261600
[TBL] [Abstract][Full Text] [Related]
11. SATB2 protein expression by immunohistochemistry is a sensitive and specific marker of appendiceal and rectosigmoid well differentiated neuroendocrine tumours.
Hoskoppal D; Epstein JI; Gown AM; Arnold Egloff SA; Gordetsky JB; Shi CJ; Giannico GA
Histopathology; 2020 Mar; 76(4):550-559. PubMed ID: 31595536
[TBL] [Abstract][Full Text] [Related]
12. Loss of SATB2 Expression Is a Biomarker of Inflammatory Bowel Disease-associated Colorectal Dysplasia and Adenocarcinoma.
Ma C; Henn P; Miller C; Herbst C; Hartman DJ; Pai RK
Am J Surg Pathol; 2019 Oct; 43(10):1314-1322. PubMed ID: 31318711
[TBL] [Abstract][Full Text] [Related]
13. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study.
Mezheyeuski A; Ponten F; Edqvist PH; Sundström M; Thunberg U; Qvortrup C; Pfeiffer P; Sorbye H; Glimelius B; Dragomir A
Acta Oncol; 2020 Mar; 59(3):284-290. PubMed ID: 31769323
[No Abstract] [Full Text] [Related]
14. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.
Matsushima J; Yazawa T; Suzuki M; Takahashi Y; Ota S; Nakajima T; Yoshino I; Yokose T; Inoue T; Kawahara K; Nakatani Y
Hum Pathol; 2017 Jun; 64():179-185. PubMed ID: 28438615
[TBL] [Abstract][Full Text] [Related]
15. SATB2 is a novel marker of osteoblastic differentiation and colorectal adenocarcinoma.
Ordóñez NG
Adv Anat Pathol; 2014 Jan; 21(1):63-7. PubMed ID: 24316906
[TBL] [Abstract][Full Text] [Related]
16. The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas.
Machado I; Navarro S; Picci P; Llombart-Bosch A
Pathol Res Pract; 2016 Sep; 212(9):811-6. PubMed ID: 27465835
[TBL] [Abstract][Full Text] [Related]
17. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.
Nodin B; Johannesson H; Wangefjord S; O'Connor DP; Lindquist KE; Uhlén M; Jirström K; Eberhard J
Diagn Pathol; 2012 Aug; 7():115. PubMed ID: 22935204
[TBL] [Abstract][Full Text] [Related]
18. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
19. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer.
Wang S; Zhou J; Wang XY; Hao JM; Chen JZ; Zhang XM; Jin H; Liu L; Zhang YF; Liu J; Ding YQ; Li JM
J Pathol; 2009 Sep; 219(1):114-22. PubMed ID: 19557828
[TBL] [Abstract][Full Text] [Related]
20. Special AT-rich sequence-binding protein 2 (SATB2) expression is sensitive but may not be specific for osteosarcoma as compared with other high-grade primary bone sarcomas.
Davis JL; Horvai AE
Histopathology; 2016 Jul; 69(1):84-90. PubMed ID: 26644288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
